000128262 001__ 128262
000128262 005__ 20240228135049.0
000128262 0247_ $$2doi$$a10.18632/oncotarget.1839
000128262 0247_ $$2pmid$$apmid:25071017
000128262 0247_ $$2pmc$$apmc:PMC4171600
000128262 0247_ $$2altmetric$$aaltmetric:2553828
000128262 037__ $$aDKFZ-2017-04279
000128262 041__ $$aeng
000128262 082__ $$a610
000128262 1001_ $$aSchipper, Holger$$b0
000128262 245__ $$aEradication of metastatic melanoma through cooperative expression of RNA-based HDAC1 inhibitor and p73 by oncolytic adenovirus.
000128262 260__ $$a[S.l.]$$bImpact Journals LLC$$c2014
000128262 3367_ $$2DRIVER$$aarticle
000128262 3367_ $$2DataCite$$aOutput Types/Journal article
000128262 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1525332124_2482
000128262 3367_ $$2BibTeX$$aARTICLE
000128262 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128262 3367_ $$00$$2EndNote$$aJournal Article
000128262 520__ $$aMalignant melanoma is a highly aggressive cancer that retains functional p53 and p73, and drug unresponsiveness largely depends on defects in death pathways after epigenetic gene silencing in conjunction with an imbalanced p73/DNp73 ratio. We constructed oncolytic viruses armed with an inhibitor of deacetylation and/or p73 to specifically target metastatic cancer. Arming of the viruses is aimed at lifting epigenetic blockage and re-opening apoptotic programs in a staggered manner enabling both, efficient virus replication and balanced destruction of target cells through apoptosis. Our results showed that cooperative expression of shHDAC1 and p73 efficiently enhances apoptosis induction and autophagy of infected cells which reinforces progeny production. In vitro analyses revealed 100% cytotoxicity after infecting cells with OV.shHDAC1.p73 at a lower virus dose compared to control viruses. Intriguingly, OV.shHDAC1.p73 acts as a potent inhibitor of highly metastatic xenograft tumors in vivo. Tumor expansion was significantly reduced after intratumoral injection of 3 x 10⁸ PFU of either OV.shHDAC1 or OV.p73 and, most important, complete regression could be achieved in 100 % of tumors treated with OV.shHDAC1.p73. Our results point out that the combination of high replication capacity and simultaneous restoration of cell death routes significantly enhance antitumor activity.
000128262 536__ $$0G:(DE-HGF)POF3-316$$a316 - Infections and cancer (POF3-316)$$cPOF3-316$$fPOF III$$x0
000128262 588__ $$aDataset connected to CrossRef, PubMed,
000128262 650_7 $$2NLM Chemicals$$aDNA-Binding Proteins
000128262 650_7 $$2NLM Chemicals$$aNuclear Proteins
000128262 650_7 $$2NLM Chemicals$$aRNA, Small Interfering
000128262 650_7 $$2NLM Chemicals$$aTumor Protein p73
000128262 650_7 $$2NLM Chemicals$$aTumor Suppressor Proteins
000128262 650_7 $$2NLM Chemicals$$ap73 protein, human
000128262 650_7 $$0EC 3.5.1.98$$2NLM Chemicals$$aHDAC1 protein, human
000128262 650_7 $$0EC 3.5.1.98$$2NLM Chemicals$$aHistone Deacetylase 1
000128262 7001_ $$aAlla, Vijay$$b1
000128262 7001_ $$aMeier, Claudia$$b2
000128262 7001_ $$0P:(DE-He78)a074bc4fb40eed64043b5d34b4d6d523$$aNettelbeck, Dirk$$b3$$udkfz
000128262 7001_ $$aHerchenröder, Ottmar$$b4
000128262 7001_ $$aPützer, Brigitte M$$b5
000128262 773__ $$0PERI:(DE-600)2560162-3$$a10.18632/oncotarget.1839$$gVol. 5, no. 15, p. 5893 - 5907$$n15$$p5893 - 5907$$tOncoTarget$$v5$$x1949-2553$$y2014
000128262 909CO $$ooai:inrepo02.dkfz.de:128262$$pVDB
000128262 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a074bc4fb40eed64043b5d34b4d6d523$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000128262 9131_ $$0G:(DE-HGF)POF3-316$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfections and cancer$$x0
000128262 9141_ $$y2014
000128262 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOTARGET : 2015
000128262 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128262 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128262 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128262 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128262 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128262 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128262 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128262 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bONCOTARGET : 2015
000128262 9201_ $$0I:(DE-He78)F110-20160331$$kF110$$lOnkolytische Adenoviren$$x0
000128262 980__ $$ajournal
000128262 980__ $$aVDB
000128262 980__ $$aI:(DE-He78)F110-20160331
000128262 980__ $$aUNRESTRICTED